The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).1
- An Epinephrine Nasal Spray (neffy) for Anaphylaxis
- Vonoprazan (Voquezna) for Nonerosive GERD
- A New RSV Vaccine (mResvia) for Adults ≥60 Years Old
- In Brief: New Warning for Fezolinetant (Veozah)
- Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old (online only)
- Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)
- Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only)
- In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)
- In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation (online only)
ISSUE
The FDA has approved an epinephrine nasal spray (neffy – ARS Pharma) for emergency treatment of type 1 hypersensitivity reactions including anaphylaxis in patients who weigh ≥30 kg. It is the first noninjectable epinephrine product to be approved for this indication.
INJECTABLE EPINEPHRINE — Multiple epinephrine auto-injector formulations are available for emergency treatment of anaphylaxis (see Table 1). EpiPen and its generics have been used effectively for years. A generic version of Adrenaclick (brand no longer manufactured) is similar to EpiPen in size and functionality. AUVI-Q provides visual signals and audio instructions, has an automatic needle retraction system, and appears to be more convenient to carry and easier to use than EpiPen.1 Because of differences in …